bluebird bio, Inc. (NASDAQ:BLUE)‘s stock had its “outperform” rating restated by equities research analysts at Leerink Swann in a report released on Friday, October 6th. They currently have a $145.00 price target on the biotechnology company’s stock, up from their previous price target of $120.00. Leerink Swann’s price target would indicate a potential upside of 4.24% from the stock’s previous close. Leerink Swann also issued estimates for bluebird bio’s FY2019 earnings at ($6.15) EPS and FY2020 earnings at ($1.72) EPS.
A number of other research analysts have also weighed in on BLUE. Cowen and Company reaffirmed an “outperform” rating on shares of bluebird bio in a research note on Friday, June 9th. Morgan Stanley reissued an “equal weight” rating and issued a $105.00 target price (up from $91.00) on shares of bluebird bio in a research note on Wednesday, June 14th. Standpoint Research reissued a “reduce” rating and issued a $110.00 target price on shares of bluebird bio in a research note on Friday, June 16th. BidaskClub raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research note on Friday, June 23rd. Finally, Wedbush reissued an “outperform” rating and issued a $100.00 target price (down from $121.00) on shares of bluebird bio in a research note on Friday, June 23rd. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. bluebird bio presently has a consensus rating of “Hold” and an average target price of $118.81.
bluebird bio (NASDAQ BLUE) opened at 139.10 on Friday. The stock’s 50 day moving average price is $129.80 and its 200-day moving average price is $103.40. The stock’s market cap is $6.34 billion. bluebird bio has a 12 month low of $37.05 and a 12 month high of $143.50.
bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.66) by ($0.07). The company had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s revenue for the quarter was up 977.4% on a year-over-year basis. During the same period in the prior year, the business posted ($1.59) earnings per share. Analysts anticipate that bluebird bio will post ($6.80) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://baseballnewssource.com/markets/leerink-swann-reiterates-outperform-rating-for-bluebird-bio-inc-blue/1703005.html.
In related news, Director Daniel Lynch sold 500 shares of the business’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the sale, the director now directly owns 3,300 shares of the company’s stock, valued at $396,000. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Eric Sullivan sold 861 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $93.83, for a total transaction of $80,787.63. Following the completion of the sale, the insider now directly owns 5,924 shares of the company’s stock, valued at $555,848.92. The disclosure for this sale can be found here. Over the last three months, insiders sold 131,779 shares of company stock valued at $16,038,514. 3.90% of the stock is owned by corporate insiders.
Several large investors have recently made changes to their positions in BLUE. QS Investors LLC raised its holdings in shares of bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 500 shares during the last quarter. Bank of Montreal Can raised its holdings in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 911 shares during the last quarter. Turner Investments LLC acquired a new position in shares of bluebird bio during the second quarter worth about $184,000. SG Americas Securities LLC increased its stake in shares of bluebird bio by 17.9% during the second quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 295 shares during the period. Finally, Fairfield Bush & CO. acquired a new position in shares of bluebird bio during the second quarter worth about $210,000.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.